Literature DB >> 24497631

Identification and validation of modulators of exchange protein activated by cAMP (Epac) activity: structure-function implications for Epac activation and inhibition.

Loren M Brown1, Kathleen E Rogers, J Andrew McCammon, Paul A Insel.   

Abstract

The signaling molecule cAMP primarily mediates its effects by activating PKA and/or exchange protein activated by cAMP (Epac). Epac has been implicated in many responses in cells, but its precise roles have been difficult to define in the absence of Epac inhibitors. Epac, a guanine nucleotide exchange factor for the low molecular weight G protein Rap, is directly activated by cAMP. Using a bioluminescence resonance energy transfer-based assay (CAMYEL) to examine modulators of Epac activity, we took advantage of its intramolecular movement that occurs upon cAMP binding to assess Epac activation. We found that the use of CAMYEL can detect the binding of cAMP analogs to Epac and their modulation of its activity and can distinguish between agonists (cAMP), partial agonists (8-chlorophenylthio-cAMP), and super agonists (8-chlorophenylthio-2'-O-Me-cAMP). The CAMYEL assay can also identify competitive and uncompetitive Epac inhibitors, e.g. (Rp)-cAMPS and CE3F4, respectively. To confirm the results with the CAMYEL assay, we used Swiss 3T3 cells and assessed the ability of cyclic nucleotide analogs to modulate the activity of Epac or PKA, determined by Rap1 activity or VASP phosphorylation, respectively. We used computational molecular modeling to analyze the interaction of analogs with Epac1. The results reveal a rapid means to identify modulators (potentially including allosteric inhibitors) of Epac activity that also provides insight into the mechanisms of Epac activation and inhibition.

Entities:  

Keywords:  Bioluminescence Resonance Energy Transfer (BRET); Cyclic AMP (cAMP); Enzyme Inhibitors; Epac1; Guanine Nucleotide Exchange Factor (GEF); Molecular Docking; Molecular Pharmacology

Mesh:

Substances:

Year:  2014        PMID: 24497631      PMCID: PMC3961650          DOI: 10.1074/jbc.M114.548636

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  39 in total

1.  A new mathematical model for relative quantification in real-time RT-PCR.

Authors:  M W Pfaffl
Journal:  Nucleic Acids Res       Date:  2001-05-01       Impact factor: 16.971

2.  Mechanism of regulation of the Epac family of cAMP-dependent RapGEFs.

Authors:  J de Rooij; H Rehmann; M van Triest; R H Cool; A Wittinghofer; J L Bos
Journal:  J Biol Chem       Date:  2000-07-07       Impact factor: 5.157

3.  Cell cycle-dependent subcellular localization of exchange factor directly activated by cAMP.

Authors:  Jingbo Qiao; Fang C Mei; Vsevolod L Popov; Leoncio A Vergara; Xiaodong Cheng
Journal:  J Biol Chem       Date:  2002-05-08       Impact factor: 5.157

Review 4.  The use of resonance energy transfer in high-throughput screening: BRET versus FRET.

Authors:  Nicolas Boute; Ralf Jockers; Tarik Issad
Journal:  Trends Pharmacol Sci       Date:  2002-08       Impact factor: 14.819

5.  Cyclic nucleotide research -- still expanding after half a century.

Authors:  Joseph A Beavo; Laurence L Brunton
Journal:  Nat Rev Mol Cell Biol       Date:  2002-09       Impact factor: 94.444

6.  A novel Epac-specific cAMP analogue demonstrates independent regulation of Rap1 and ERK.

Authors:  Jorrit M Enserink; Anne E Christensen; Johan de Rooij; Miranda van Triest; Frank Schwede; Hans Gottfried Genieser; Stein O Døskeland; Jonathan L Blank; Johannes L Bos
Journal:  Nat Cell Biol       Date:  2002-11       Impact factor: 28.824

7.  cAMP-GEFII is a direct target of cAMP in regulated exocytosis.

Authors:  N Ozaki; T Shibasaki; Y Kashima; T Miki; K Takahashi; H Ueno; Y Sunaga; H Yano; Y Matsuura; T Iwanaga; Y Takai; S Seino
Journal:  Nat Cell Biol       Date:  2000-11       Impact factor: 28.824

Review 8.  Cyclic nucleotide analogs as biochemical tools and prospective drugs.

Authors:  F Schwede; E Maronde; H Genieser; B Jastorff
Journal:  Pharmacol Ther       Date:  2000 Aug-Sep       Impact factor: 12.310

9.  Ligand-mediated activation of the cAMP-responsive guanine nucleotide exchange factor Epac.

Authors:  Holger Rehmann; Frank Schwede; Stein O Døskeland; Alfred Wittinghofer; Johannes L Bos
Journal:  J Biol Chem       Date:  2003-07-29       Impact factor: 5.157

10.  cAMP analog mapping of Epac1 and cAMP kinase. Discriminating analogs demonstrate that Epac and cAMP kinase act synergistically to promote PC-12 cell neurite extension.

Authors:  Anne E Christensen; Frode Selheim; Johan de Rooij; Sarah Dremier; Frank Schwede; Khanh K Dao; Aurora Martinez; Carine Maenhaut; Johannes L Bos; H-G Genieser; Stein O Døskeland
Journal:  J Biol Chem       Date:  2003-06-20       Impact factor: 5.157

View more
  10 in total

1.  Rp-cAMPS Prodrugs Reveal the cAMP Dependence of First-Phase Glucose-Stimulated Insulin Secretion.

Authors:  Frank Schwede; Oleg G Chepurny; Melanie Kaufholz; Daniela Bertinetti; Colin A Leech; Over Cabrera; Yingmin Zhu; Fang Mei; Xiaodong Cheng; Jocelyn E Manning Fox; Patrick E MacDonald; Hans-G Genieser; Friedrich W Herberg; George G Holz
Journal:  Mol Endocrinol       Date:  2015-06-10

Review 2.  Intracellular cAMP Sensor EPAC: Physiology, Pathophysiology, and Therapeutics Development.

Authors:  William G Robichaux; Xiaodong Cheng
Journal:  Physiol Rev       Date:  2018-04-01       Impact factor: 37.312

3.  Allosteric inhibition of Epac: computational modeling and experimental validation to identify allosteric sites and inhibitors.

Authors:  Loren M Brown; Kathleen E Rogers; Nakon Aroonsakool; J Andrew McCammon; Paul A Insel
Journal:  J Biol Chem       Date:  2014-09-02       Impact factor: 5.157

4.  Different downstream signalling of CCK1 receptors regulates distinct functions of CCK in pancreatic beta cells.

Authors:  Shang-lei Ning; Wen-shuai Zheng; Jing Su; Nan Liang; Hui Li; Dao-lai Zhang; Chun-hua Liu; Jun-hong Dong; Zheng-kui Zhang; Min Cui; Qiao-Xia Hu; Chao-chao Chen; Chang-hong Liu; Chuan Wang; Qi Pang; Yu-xin Chen; Xiao Yu; Jin-peng Sun
Journal:  Br J Pharmacol       Date:  2015-10-23       Impact factor: 8.739

Review 5.  The future of EPAC-targeted therapies: agonism versus antagonism.

Authors:  Euan Parnell; Timothy M Palmer; Stephen J Yarwood
Journal:  Trends Pharmacol Sci       Date:  2015-03-03       Impact factor: 14.819

6.  Vasoactive intestinal peptide increases apoptosis of hepatocellular carcinoma by inhibiting the cAMP/Bcl-xL pathway.

Authors:  Masaki Hara; Yuko Takeba; Taroh Iiri; Yuki Ohta; Masanori Ootaki; Minoru Watanabe; Daiki Watanabe; Satoshi Koizumi; Takehito Otsubo; Naoki Matsumoto
Journal:  Cancer Sci       Date:  2018-12-04       Impact factor: 6.716

7.  A PKA/cdc42 Signaling Axis Restricts Angiogenic Sprouting by Regulating Podosome Rosette Biogenesis and Matrix Remodeling.

Authors:  J L MacKeil; P Brzezinska; J Burke-Kleinman; A W Craig; C J B Nicol; D H Maurice
Journal:  Sci Rep       Date:  2019-02-20       Impact factor: 4.379

8.  Attenuation of chemokine receptor function and surface expression as an immunomodulatory strategy employed by human cytomegalovirus is linked to vGPCR US28.

Authors:  Theresa Frank; Anna Reichel; Olav Larsen; Anne-Charlotte Stilp; Mette M Rosenkilde; Thomas Stamminger; Takeaki Ozawa; Nuska Tschammer
Journal:  Cell Commun Signal       Date:  2016-12-12       Impact factor: 5.712

Review 9.  The Epac1 Protein: Pharmacological Modulators, Cardiac Signalosome and Pathophysiology.

Authors:  Marion Bouvet; Jean-Paul Blondeau; Frank Lezoualc'h
Journal:  Cells       Date:  2019-11-29       Impact factor: 6.600

Review 10.  Recent Advances in EPAC-Targeted Therapies: A Biophysical Perspective.

Authors:  Alveena Ahmed; Stephen Boulton; Hongzhao Shao; Madoka Akimoto; Amarnath Natarajan; Xiaodong Cheng; Giuseppe Melacini
Journal:  Cells       Date:  2019-11-19       Impact factor: 6.600

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.